2021.09.01 – The Cutting Edge of Mild Traumatic Brain Injury (mTBI): Providing an Objective Assessment to Brain Injury Evaluation Using Biomarkers (Recorded Webinar)

A Robert Sbordone Memorial mTBI/Concussion Lecture recorded webinar featuring Jeff Bazarian, M.D., M.P.H., Paul Jarvis, M.D., and Jesse M. Pines, M.D.

If you select "Add to Basket" below, you will be prompted to continue to payment. When you have completed the checkout process, you will receive an email with further instructions. The file contained in this email also includes instructions for receiving your ACBIS CEU.

Select this box to receive helpful information from Abbott Laboratories in the future.

*To read the full opt-in disclaimer, scroll down.

 Aired live September 1, 2021. Includes 1 ACBIS CEU.

Traumatic brain injury (TBI) is evaluated during ~5 million ED visits annually1 of which more than 80% are classified as mild (GCS 13 to 15)2. Due to the limitations of current evaluation tools, mTBI assessment can be time- and resource-consuming.

In this webinar, leading experts discuss the latest research into blood-based biomarkers and their potential to predict the absence of intracranial injury. You’ll also hear how two proteins, Ubiquitin C-terminal hydrolase-L1 (UCH-L1) and Glial fibrillary acidic protein (GFAP), have emerged as promising biomarkers that can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients in the ED.

Learning Objectives:

  1. Examine challenges and shortcomings of the current approaches to mTBI evaluation in the ED
  2. Understand the latest advancements in TBI biomarkers, including identifying brain-specific biomarkers with characteristics that offer diagnostic value in the ED
  3. Understand how blood-based biomarker testing can be used in conjunction with other clinical information to aid in the evaluation of suspected mTBI patients
  4. Learn how blood-based biomarker testing in the ED can reduce diagnostic uncertainty by providing a quantifiable objective assessment to inform the evaluation of suspected mTBI
  5. Examine the potential for biomarker testing to reduce unnecessary head CT, improve patient care and satisfaction, and improve operational efficiency


Jeffrey J. Bazarian, M.D., M.P.H.
Professor of Emergency Medicine, University of Rochester School of Medicine

Paul Jarvis, M.D.
Emergency Medicine Physician, Director of Global Medical Affairs, Abbott Point of Care

Jesse M. Pines, M.D., M.B.A., M.S.C.E.
National Director of Clinical Innovation, U.S. Acute Care Solutions and Professor of Emergency Medicine, Drexel University


Korley FK et al. J Head Trauma Rehabil. 2016;31(6):379-387.
Dewan MC et al. J Neurosurg. 2004;43(suppl):113-125.


By selecting yes above, I agree that my information will be shared with webinar partner Abbott and that: (1) the information I've provided will be used only by Abbott Point of Care, its affiliates, and contracted third parties to mail, telephone, and email me helpful information on products and services, and for marketing and information purposes, (2) Abbott Point of Care will not sell or transfer my name or contact information to any third party for its marketing use, (3) I may be removed from Abbott Point of Care’s mailing list or request a copy of this information by contacting 1-609-454-9000. In the event this form is incomplete or filled out incorrectly, Abbott Point of Care may contact you for further clarification, (4) Abbott Point of Care stores my personal information securely and in accordance with applicable laws and standards, (5) Abbott Point of Care may transmit my personal information to other Abbott locations worldwide, including other countries that may not have the same data protection requirements as my country. However, Abbott Point of Care and all its affiliates and locations worldwide are required to protect and treat my personal information in a manner consistent with this notice and in accordance with Abbott Point of Care’s policies and applicable laws. For further information about Abbott’s privacy policy, please read the applicable privacy policy for your country.